136 related articles for article (PubMed ID: 25318697)
1. Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study.
Coller JK; White IA; Logan RM; Tuke J; Richards AM; Mead KR; Karapetis CS; Bowen JM
Support Care Cancer; 2015 May; 23(5):1233-6. PubMed ID: 25318697
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy.
Korver SK; Gibson RJ; Bowen JM; Coller JK
Cancer Chemother Pharmacol; 2019 Feb; 83(2):217-236. PubMed ID: 30474704
[TBL] [Abstract][Full Text] [Related]
3. The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy-induced gastrointestinal toxicity.
Secombe KR; Coller JK; Gibson RJ; Wardill HR; Bowen JM
Int J Cancer; 2019 May; 144(10):2365-2376. PubMed ID: 30155890
[TBL] [Abstract][Full Text] [Related]
4. Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.
Bowen JM; White I; Smith L; Tsykin A; Kristaly K; Thompson SK; Karapetis CS; Tan H; Game PA; Irvine T; Hussey DJ; Watson DI; Keefe DM
Support Care Cancer; 2015 Nov; 23(11):3165-72. PubMed ID: 25814442
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced gastrointestinal toxicity: Pathogenesis and current management.
He Y; Zheng J; Ye B; Dai Y; Nie K
Biochem Pharmacol; 2023 Oct; 216():115787. PubMed ID: 37666434
[TBL] [Abstract][Full Text] [Related]
6. Modulation of 5-fluorouracil activation of toll-like/MyD88/NF-κB/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic.
Justino PFC; Franco AX; Pontier-Bres R; Monteiro CES; Barbosa ALR; Souza MHLP; Czerucka D; Soares PMG
Cytokine; 2020 Jan; 125():154791. PubMed ID: 31401369
[TBL] [Abstract][Full Text] [Related]
7. Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
Dranitsaris G; Shah A; Spirovski B; Vincent M
Clin Colorectal Cancer; 2007 Jan; 6(5):367-73. PubMed ID: 17311702
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
[TBL] [Abstract][Full Text] [Related]
9. Peptidoglycan Recognition Peptide 2 Aggravates Weight Loss in a Murine Model of Chemotherapy-Induced Gastrointestinal Toxicity.
Bech AS; Nexoe AB; Dubik M; Moeller JB; Soerensen GL; Holmskov U; Madsen GI; Husby S; Rathe M
Front Oncol; 2021; 11():635005. PubMed ID: 33833993
[No Abstract] [Full Text] [Related]
10. Fluorouracil-based chemotherapy in patients with gastrointestinal malignancies: influence of nutritional folate status on toxicity.
Alvarez-Cabellos R; Garcia-Carbonero R; Garcia-Lacalle C; Gomez P; Tercero A; Sanchez D; Paz-Ares L
J Chemother; 2007 Dec; 19(6):744-9. PubMed ID: 18230560
[TBL] [Abstract][Full Text] [Related]
11. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients.
Yin JY; Li X; Li XP; Xiao L; Zheng W; Chen J; Mao CX; Fang C; Cui JJ; Guo CX; Zhang W; Gao Y; Zhang CF; Chen ZH; Zhou H; Zhou HH; Liu ZQ
Cancer Lett; 2016 Jul; 377(1):65-73. PubMed ID: 27126360
[TBL] [Abstract][Full Text] [Related]
12. Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
Farker K; Merkel U; Wedding U; Hippius M; Höffken K; Hoffmann A
Int J Clin Pharmacol Ther; 2006 Jan; 44(1):31-7. PubMed ID: 16425969
[TBL] [Abstract][Full Text] [Related]
13. Mice lacking myeloid differentiation factor 88 display profound defects in host resistance and immune responses to Mycobacterium avium infection not exhibited by Toll-like receptor 2 (TLR2)- and TLR4-deficient animals.
Feng CG; Scanga CA; Collazo-Custodio CM; Cheever AW; Hieny S; Caspar P; Sher A
J Immunol; 2003 Nov; 171(9):4758-64. PubMed ID: 14568952
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats.
Forsgård RA; Marrachelli VG; Korpela K; Frias R; Collado MC; Korpela R; Monleon D; Spillmann T; Österlund P
Cancer Chemother Pharmacol; 2017 Aug; 80(2):317-332. PubMed ID: 28646338
[TBL] [Abstract][Full Text] [Related]
15. The R753Q polymorphism in Toll-like receptor 2 (TLR2) attenuates innate immune responses to mycobacteria and impairs MyD88 adapter recruitment to TLR2.
Pattabiraman G; Panchal R; Medvedev AE
J Biol Chem; 2017 Jun; 292(25):10685-10695. PubMed ID: 28442574
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M
Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489
[TBL] [Abstract][Full Text] [Related]
17. TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy.
Roselli M; Ferroni P; Rolfo C; Peeters M; Palmirotta R; Formica V; Ludovici G; Laudisi A; De Marchis ML; La Farina F; Russo A; Guadagni F
Ann Oncol; 2013 Oct; 24(10):2571-2575. PubMed ID: 23852308
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
Onesti CE; Botticelli A; La Torre M; Borro M; Gentile G; Romiti A; Lionetto L; Petremolo A; Occhipinti M; Roberto M; Falcone R; Simmaco M; Marchetti P; Mazzuca F
Anticancer Drugs; 2017 Mar; 28(3):322-326. PubMed ID: 27845948
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity.
Cario E
Curr Opin Support Palliat Care; 2016 Jun; 10(2):157-64. PubMed ID: 26986508
[TBL] [Abstract][Full Text] [Related]
20. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.
Cespedes Feliciano EM; Lee VS; Prado CM; Meyerhardt JA; Alexeeff S; Kroenke CH; Xiao J; Castillo AL; Caan BJ
Cancer; 2017 Dec; 123(24):4868-4877. PubMed ID: 28881381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
